 Patients with CD and fistula have a decreased quality of life. Reasons include perianal pain, discharge from the vagina, abdominal wall, perianal region and urinary tract infections. Fistula are frequently associated with abscess formation 8. Unfortunately, surgical and medical treatment options for fistula for CD patients remain limited. Treatment with the tumor-necrosis factor TNF antibody infliximab remains the best medical treatment option available: At least temporary fistula closure is observed for 55 of treated fistula compared to 12 for placebo. However, treatment success is frequently limited to a short time period of 3 month 9, 10: 34 of all fistula patients experience recurrent fistula despite therapy 6 and successful treatment is limited to one third patients. For these reasons, up to 82 of all fistula need surgical treatment. Surgical options include non-cutting setons, application of fibrin glue as a fistula plug, ligation of the intersphincteric fistula tract LIFT and reparative surgery including mucosal advancement flaps. However, surgical therapy for fistula patients can be complicated by slow wound healing, recurrent disease and additional problems 11. 